Rodent Models for Alzheimer's Disease Drug Discovery

Overview

Journal Expert Opin Drug Discov

Specialties Chemistry
Pharmacology

Date 2015 May 1

PMID 25927677

Citations 91

Authors

Daniela Puzzo

Walter Gulisano

Agostino Palmeri

Ottavio Arancio

Affiliations

Soon will be listed here.

Abstract

Introduction: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and personality changes, leading to dementia. Histopathological hallmarks are represented by aggregates of beta-amyloid peptide (Aβ) in senile plaques and deposition of hyperphosphorylated tau protein in neurofibrillary tangles in the brain. Rare forms of early onset familial Alzheimer's disease are due to gene mutations. This has prompted researchers to develop genetically modified animals that could recapitulate the main features of the disease. The use of these models is complemented by non-genetically modified animals.

Areas Covered: This review summarizes the characteristics of the most used transgenic (Tg) and non-Tg models of AD. The authors have focused on models mainly used in their laboratories including amyloid precursor protein (APP) Tg2576, APP/presenilin 1, 3xAD, single h-Tau, non-Tg mice treated with acute injections of Aβ or tau, and models of physiological aging.

Expert Opinion: Animal models of disease might be very useful for studying the pathophysiology of the disease and for testing new therapeutics in preclinical studies but they do not reproduce the entire clinical features of human AD. When selecting a model, researchers should consider the various factors that might influence the phenotype. They should also consider the timing of testing/treating animals since the age at which each model develops certain aspects of the AD pathology varies.

Citing Articles

Alterations of endocannabinoid signaling and microglia reactivity in the retinas of AD-like mice precede the onset of hippocampal β-amyloid plaques.

Tisi A, Scipioni L, Carozza G, Di Re L, Cimino G, Di Meo C J Neurochem. 2024; 169(2):e16256.

PMID: 39556462 PMC: 11808635. DOI: 10.1111/jnc.16256.

Cannula Implantation Reduces the Severity of the Beta Amyloid Effect on Peroxidized Lipids and Glutathione Levels in the Brain of BALB/c Mice.

Mukhina K, Mitkevich V, Popova I Acta Naturae. 2024; 16(3):51-59.

PMID: 39555175 PMC: 11569840. DOI: 10.32607/actanaturae.27439.

Pharmacological inhibition of PLK2 kinase activity mitigates cognitive decline but aggravates APP pathology in a sex-dependent manner in APP/PS1 mouse model of Alzheimer's disease.

Martinez-Drudis L, Berard M, Musiol D, Rivest S, Oueslati A Heliyon. 2024; 10(20):e39571.

PMID: 39498012 PMC: 11532864. DOI: 10.1016/j.heliyon.2024.e39571.

A Comprehensive Review on Preclinical Alzheimer's Disease Models: Evaluating their Clinical Relevance.

Kushwaha V, Kumar Sahu K Curr Pharm Biotechnol. 2024; 26(2):186-207.

PMID: 39161136 DOI: 10.2174/0113892010331845240802073645.

MAMs and Mitochondrial Quality Control: Overview and Their Role in Alzheimer's Disease.

Luo J, Zhai W, Ding L, Zhang X, Han J, Ning J Neurochem Res. 2024; 49(10):2682-2698.

PMID: 39002091 DOI: 10.1007/s11064-024-04205-w.

References

Billings L, Oddo S, Green K, McGaugh J, LaFerla F . Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005; 45(5):675-88. DOI: 10.1016/j.neuron.2005.01.040. View

Ma Q, Zuo X, Yang F, Ubeda O, Gant D, Alaverdyan M . Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem. 2012; 288(6):4056-65. PMC: 3567657. DOI: 10.1074/jbc.M112.393751. View

Bertoni-Freddari C, Sensi S, Giorgetti B, Balietti M, Di Stefano G, Canzoniero L . Decreased presence of perforated synapses in a triple-transgenic mouse model of Alzheimer's disease. Rejuvenation Res. 2008; 11(2):309-13. DOI: 10.1089/rej.2008.0660. View

Balducci C, Forloni G . In vivo application of beta amyloid oligomers: a simple tool to evaluate mechanisms of action and new therapeutic approaches. Curr Pharm Des. 2013; 20(15):2491-505. DOI: 10.2174/13816128113199990497. View

Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C . Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995; 373(6514):523-7. DOI: 10.1038/373523a0. View

Sierksma A, van den Hove D, Pfau F, Philippens M, Bruno O, Fedele E . Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Neuropharmacology. 2013; 77:120-30. DOI: 10.1016/j.neuropharm.2013.09.015. View

Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S . Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996; 274(5284):99-102. DOI: 10.1126/science.274.5284.99. View

Polydoro M, Acker C, Duff K, Castillo P, Davies P . Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009; 29(34):10741-9. PMC: 2760256. DOI: 10.1523/JNEUROSCI.1065-09.2009. View

Trinchese F, Liu S, Battaglia F, Walter S, Mathews P, Arancio O . Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol. 2004; 55(6):801-14. DOI: 10.1002/ana.20101. View

10.

Yeoman M, Scutt G, Faragher R . Insights into CNS ageing from animal models of senescence. Nat Rev Neurosci. 2012; 13(6):435-45. DOI: 10.1038/nrn3230. View

11.

Holcomb L, Gordon M, McGowan E, Yu X, Benkovic S, Jantzen P . Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998; 4(1):97-100. DOI: 10.1038/nm0198-097. View

12.

Chen G, Chen K, Knox J, Inglis J, Bernard A, Martin S . A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 2001; 408(6815):975-9. DOI: 10.1038/35050103. View

13.

Castillo-Carranza D, Gerson J, Sengupta U, Guerrero-Munoz M, Lasagna-Reeves C, Kayed R . Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J Alzheimers Dis. 2014; 40 Suppl 1:S97-S111. DOI: 10.3233/JAD-132477. View

14.

Treuting P, Hopkins H, Ware C, Rabinovitch P, Ladiges W . Generation of genetically altered mouse models for aging studies. Exp Mol Pathol. 2002; 72(1):49-55. DOI: 10.1006/exmp.2001.2405. View

15.

Gimenez-Llort L, Blazquez G, Canete T, Johansson B, Oddo S, Tobena A . Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev. 2006; 31(1):125-47. DOI: 10.1016/j.neubiorev.2006.07.007. View

16.

Puzzo D, Loreto C, Giunta S, Musumeci G, Frasca G, Podda M . Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. Neurobiol Aging. 2013; 35(3):520-31. PMC: 8966201. DOI: 10.1016/j.neurobiolaging.2013.09.002. View

17.

Duff K, Eckman C, Zehr C, Yu X, Prada C, Perez-Tur J . Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996; 383(6602):710-3. DOI: 10.1038/383710a0. View

18.

Quon D, Wang Y, Catalano R, Scardina J, Murakami K, Cordell B . Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature. 1991; 352(6332):239-41. DOI: 10.1038/352239a0. View

19.

Sterniczuk R, Antle M, LaFerla F, Dyck R . Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 2. Behavioral and cognitive changes. Brain Res. 2010; 1348:149-55. DOI: 10.1016/j.brainres.2010.06.011. View

20.

King D, Arendash G . Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav. 2002; 75(5):627-42. DOI: 10.1016/s0031-9384(02)00639-x. View